TipRanks on MSN
Incyte steps into late-stage colorectal cancer race with new phase 3 trial of INCA33890
Incyte ($INCY) announced an update on their ongoing clinical study. Study Overview Incyte’s new Phase 3 trial, titled “A Randomized, Double-Blind, ...
TipRanks on MSN
BMY and BNTX advance new immunotherapy bet in first-line liver cancer with ROSETTA HCC-206
Biontech Se Sponsored Adr (BNTX), Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment. ...
Atezolizumab plus standard therapy was not associated with improved survival in advanced recurrent ovarian cancer.
CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. Read why CTMX stock ...
Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...
WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...
Background and Purpose: The lesional phenotype of human brain arteriovenous malformation (bAVM) includes increased VEGF expression compared to normal brain. We developed an adult mouse model of bAVM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback